Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ( "Purchaser" ) , has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share ( the ...
Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ( "Purchaser" ) , has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share ( the ...
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody - Tiziana Life Sciences ( NASDAQ:TLSA )
BOSTON, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- Tiziana Life Sciences, Ltd. ( NASDAQ: TLSA ) ( "Tiziana" or the "Company" ) , today announces it will advance its second asset, a fully human anti-IL-6 receptor ( "IL-6R" ) monoclonal antibody, TZLS-501.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WOW, PRO, TRML, PGRE on Behalf of Shareholders - Pros Holdings ( NYSE:PRO ) , Paramount Group ( NYSE:PGRE )
NEW YORK, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WideOpenWest, Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: PROS Holdings, Inc. ( NYSE - PROS ) , Paramount Group, Inc. ( NYSE - PGRE ) , Tourmaline Bio, Inc. ( Nasdaq - TRML ) , WideOpenWest, Inc. ( NYSE - WOW )
BALA CYNWYD, Pa., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, WOW, TRML, BTBD on Behalf of Shareholders - BT Brands ( NASDAQ:BTBD ) , Paramount Group ( NYSE:PGRE )
NEW YORK, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Paramount Group, Inc.
This New Mountain Finance Analyst Turns Bearish; Here Are Top 3 Downgrades For Monday - Array Technologies ( NASDAQ:ARRY ) , CVR Energy ( NYSE:CVI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Kostas Biliouris downgraded Tourmaline Bio, Inc.
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views - CaliberCos ( NASDAQ:CWD ) , Core & Main ( NYSE:CNM )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.33% to 45,664.09 while the NASDAQ rose 0.20% to 21,842.19. The S&P 500 also rose, gaining, 0.18% to 6,506.81. Energy shares jumped by 1.8% on Tuesday.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Tourmaline Bio, Inc. ( Nasdaq - TRML ) , BT Brands, Inc. ( Nasdaq - BTBD ) , WideOpenWest, Inc. ( NYSE - WOW ) , Workhorse Group Inc. ( Nasdaq - WKHS )
BALA CYNWYD, Pa., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday - Alibaba Gr Hldgs ( NYSE:BABA ) , Brighthouse Finl ( NASDAQ:BHF )
U.S. stocks were lower, with the Nasdaq Composite falling around 0.1% on Tuesday. Shares of Tourmaline Bio, Inc. TRML rose sharply during Tuesday's session after the company announced it entered into an agreement to be acquired by Novartis.
Why Is Tourmaline Bio Stock Skyrocketing Tuesday? - Novartis ( NYSE:NVS ) , Tourmaline Bio ( NASDAQ:TRML )
Novartis to buy Tourmaline Bio for $1.4 billion, paying $48 per share in cash at closing. Pacibekitug cut hs-CRP levels significantly by Day 90 in the Phase 2 trial vs placebo. Get the strategy to turn September's volatility into 10x trades → Tourmaline Bio, Inc.
Why Nebius Group Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket - Brighthouse Finl ( NASDAQ:BHF ) , AIRO Group Holdings ( NASDAQ:AIRO )
Shares of Nebius Group N.V. NBIS rose sharply in pre-market trading after the company announced it secured up to $19.4 billion 5-year GPU infrastructure contract with Microsoft.
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
- Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion ...
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease ( ASCVD )
• Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease • Pacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation-an independent and ...
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress - Tourmaline Bio ( NASDAQ:TRML )
- Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups -
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
- Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups -
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. ( TRML ) : Here's What You Should Know
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tourmaline Bio Reports Loss as R&D Rises
Tourmaline Bio ( NASDAQ:TRML ) , a clinical-stage biotechnology company focusing on treatments for inflammatory diseases, published its earnings for the second quarter on August 13, 2025. The most notable headline was the positive clinical milestone from its Phase 2 TRANQUILITY trial for its lead ...
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Amer Sports ( NYSE:AS ) , Ekso Bionics Holdings ( NASDAQ:EKSO )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday. The Dow traded down 0.37% to 42,632.71 while the NASDAQ fell 0.43% to 19,132.73. The S&P 500 also fell, dropping, 0.42% to 5,938.36. Utilities shares rose by 0.3% on Tuesday.
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Asana ( NYSE:ASAN ) , Elong Power Holding ( NASDAQ:ELPW )
U.S. stock futures were mixed this morning, with the Nasdaq futures falling around 0.3% on Tuesday. Shares of Trip.com Group Limited TCOM fell sharply in today's pre-market trading following weaker-than-expected quarterly earnings.
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a ...
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
- Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 -
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 - - Cardiovascular Scientific Advisory Board strengthened with recent ...
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - ImmunityBio ( NASDAQ:IBRX ) , Aduro Clean Technologies ( NASDAQ:ADUR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Andrew Fein initiated coverage on ImmunityBio, Inc.
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Beta Bionics ( NASDAQ:BBNX ) , Compass Therapeutics ( NASDAQ:CMPX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Benjamin Budish initiated coverage on Blue Owl Capital Inc.
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
Paul M. Ridker, MD, MPH, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB).
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
- Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 - - Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven ...
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
Tourmaline Bio to Host Investor Day on Tuesday, December ...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will ...
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it ...
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board - Tourmaline Bio ( NASDAQ:TRML )
- Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases - - Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the ...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
- Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases - - Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the ...
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio to Present at Upcoming Investor Conferences - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug ( TOUR006 ) in patients with high cardiovascular risk - - On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye ...
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology ( ASPC ) Congress 2024
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress ...
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology ( ASPC ) Congress 2024 - Tourmaline Bio ( NASDAQ:TRML )
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein ( hs-CRP ) -lowering effect, safety, tolerability, and pharmacokinetics ( PK ) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP -
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
NEW YORK, June 27, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, May 23, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June ...
Dow Jumps 200 Points; US Weekly Jobless Claims Fall - Intelligent Group ( NASDAQ:INTJ ) , Asset Entities ( NASDAQ:ASST )
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose 0.84% to 16,506.28. The S&P 500 also rose, gaining, 0.53% to 5,252.23.
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Five Below ( NASDAQ:FIVE ) , LexinFintech Holdings ( NASDAQ:LX )
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. Shares of Five Below, Inc. FIVE fell sharply in today's pre-market trading after the company reported fourth-quarter financial results.
